The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

floxuridine     5-fluoro-1-[(2R,4S,5R)-4- hydroxy-5...

Synonyms: Floxuridin, FdUrd, Floxiridina, FDUR, FUDR, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of floxuridine


Psychiatry related information on floxuridine


High impact information on floxuridine


Chemical compound and disease context of floxuridine


Biological context of floxuridine


Anatomical context of floxuridine


Associations of floxuridine with other chemical compounds


Gene context of floxuridine


Analytical, diagnostic and therapeutic context of floxuridine


  1. Activity of albumin conjugates of 5-fluorodeoxyuridine and cytosine arabinoside on poxviruses as a lysosomotropic approach to antiviral chemotherapy. Balboni, P.G., Minia, A., Grossi, M.P., Barbanti-Brodano, G., Mattioli, A., Fiume, L. Nature (1976) [Pubmed]
  2. Determination of the therapeutic index of floxuridine by its circadian infusion pattern. von Roemeling, R., Hrushesky, W.J. J. Natl. Cancer Inst. (1990) [Pubmed]
  3. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. Stagg, R.J., Venook, A.P., Chase, J.L., Lewis, B.J., Warren, R.S., Roh, M., Mulvihill, S.J., Grobman, B.J., Rayner, A.A., Hohn, D.C. J. Natl. Cancer Inst. (1991) [Pubmed]
  4. Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma. Cao, S., Frank, C., Rustum, Y.M. J. Natl. Cancer Inst. (1996) [Pubmed]
  5. Effect of 5-fluoro-2'-deoxyuridine on deoxyribonucleotide pools in vivo. Ritter, E.J., Scott, W.J., Wilson, J.G., Lampkin, B.C., Neely, J.E. J. Natl. Cancer Inst. (1980) [Pubmed]
  6. 5-Fluoro-2'-deoxyuridine induction of the fragile site on Xq28 associated with X linked mental retardation. Tommerup, N., Poulsen, H., Brøndum-Nielsen, K. J. Med. Genet. (1981) [Pubmed]
  7. Schedule-dependent effect of phase-specific cytotoxic agents on production of hemolytic plaque-forming cells. Lin, H. J. Natl. Cancer Inst. (1976) [Pubmed]
  8. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Allen-Mersh, T.G., Earlam, S., Fordy, C., Abrams, K., Houghton, J. Lancet (1994) [Pubmed]
  9. Fatal liver cirrhosis associated with long-term arterial infusion of floxuridine. Pettavel, J., Gardiol, D., Bergier, N., Schnyder, P. Lancet (1986) [Pubmed]
  10. Gastroduodenal mucosal injury during hepatic arterial infusion of chemotherapeutic agents. Lack of cytoprotection by prostaglandin E1 analogue. Mavligit, G.M., Faintuch, J., Levin, B., Wallace, S., Charnsangavej, C., Carrasco, C., Patt, Y.Z. Gastroenterology (1987) [Pubmed]
  11. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Meyers, M., Wagner, M.W., Hwang, H.S., Kinsella, T.J., Boothman, D.A. Cancer Res. (2001) [Pubmed]
  12. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. Lorenz, M., Müller, H.H. J. Clin. Oncol. (2000) [Pubmed]
  13. Increased growth inhibition and DNA lesions in human colon adenocarcinoma cells treated with methotrexate or 5-fluorodeoxyuridine followed by calmodulin inhibitors. Lönn, U., Lönn, S. Cancer Res. (1988) [Pubmed]
  14. Levels of thymidylate synthetase during normal culture growth of L1210 cells. Cadman, E., Heimer, R. Cancer Res. (1986) [Pubmed]
  15. Inhibition of the mammalian transcription factor LSF induces S-phase-dependent apoptosis by downregulating thymidylate synthase expression. Powell, C.M., Rudge, T.L., Zhu, Q., Johnson, L.F., Hansen, U. EMBO J. (2000) [Pubmed]
  16. Fragile (X) expression induced by FUdR is transient and inversely related to levels of thymidylate synthase activity. Cantú, E.S., Nussbaum, R.L., Airhart, S.D., Ledbetter, D.H. Am. J. Hum. Genet. (1985) [Pubmed]
  17. Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: implications for mechanisms of resistance and cytotoxicity. Canman, C.E., Tang, H.Y., Normolle, D.P., Lawrence, T.S., Maybaum, J. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  18. A nonmitogenic pituitary function of fibroblast growth factor: regulation of thyrotropin and prolactin secretion. Baird, A., Mormède, P., Ying, S.Y., Wehrenberg, W.B., Ueno, N., Ling, N., Guillemin, R. Proc. Natl. Acad. Sci. U.S.A. (1985) [Pubmed]
  19. Fragile X expression is decreased by 5-azacytidine and S-adenosylhomocysteine. Mixon, J.C., Dev, V.G. Am. J. Hum. Genet. (1983) [Pubmed]
  20. Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. Park, J.G., Collins, J.M., Gazdar, A.F., Allegra, C.J., Steinberg, S.M., Greene, R.F., Kramer, B.S. J. Natl. Cancer Inst. (1988) [Pubmed]
  21. Thymidylate synthetase overproduction in 5-fluorodeoxyuridine-resistant mouse fibroblasts. Rossana, C., Gollakota Rao, L., Johnson, L.F. Mol. Cell. Biol. (1982) [Pubmed]
  22. Tumor and liver drug uptake following hepatic artery and portal vein infusion. Sigurdson, E.R., Ridge, J.A., Kemeny, N., Daly, J.M. J. Clin. Oncol. (1987) [Pubmed]
  23. Effect of methotrexate and 5-fluorodeoxyuridine on ribonucleotide reductase activity in mammalian cells. Elford, H.L., Bonner, E.L., Kerr, B.H., Hanna, S.D., Smulson, M. Cancer Res. (1977) [Pubmed]
  24. FUdR induction of the X chromosome fragile site: evidence for the mechanism of folic acid and thymidine inhibition. Glover, T.W. Am. J. Hum. Genet. (1981) [Pubmed]
  25. Cytotoxicity of 5-fluoro-2'-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate. Ullman, B., Lee, M., Martin, D.W., Santi, D.V. Proc. Natl. Acad. Sci. U.S.A. (1978) [Pubmed]
  26. Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Romanini, A., Lin, J.T., Niedzwiecki, D., Bunni, M., Priest, D.G., Bertino, J.R. Cancer Res. (1991) [Pubmed]
  27. Development and characterization of a rat model for locally recurring mammary tumors: sensitivities to 5-fluoro-2'-deoxyuridine, adriamycin, and X-irradiation. Welch, D.R., Aeed, P.A., Estrada, J. Cancer Res. (1988) [Pubmed]
  28. Identification of the mechanism of activation of 9-beta-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases. Verhoef, V., Sarup, J., Fridland, A. Cancer Res. (1981) [Pubmed]
  29. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. Meyers, M., Wagner, M.W., Mazurek, A., Schmutte, C., Fishel, R., Boothman, D.A. J. Biol. Chem. (2005) [Pubmed]
  30. Bone morphogenetic protein-2 promotes survival and differentiation of striatal GABAergic neurons in the absence of glial cell proliferation. Hattori, A., Katayama, M., Iwasaki, S., Ishii, K., Tsujimoto, M., Kohno, M. J. Neurochem. (1999) [Pubmed]
  31. Interleukin-2 and interleukin-4 increase the survival of retinal ganglion cells in culture. Sholl-Franco, A., Figueiredo, K.G., de Araujo, E.G. Neuroreport (2001) [Pubmed]
  32. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Thomas, D.M., Zalcberg, J.R. Clin. Exp. Pharmacol. Physiol. (1998) [Pubmed]
  33. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Terashima, M., Irinoda, T., Fujiwara, H., Nakaya, T., Takagane, A., Abe, K., Yonezawa, H., Oyama, K., Inaba, T., Saito, K., Takechi, T., Fukushima, M. Anticancer Res. (2002) [Pubmed]
  34. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. Durand-Zaleski, I., Roche, B., Buyse, M., Carlson, R., O'Connell, M.J., Rougier, P., Chang, A.E., Sondak, V.K., Kemeny, M.M., Allen-Mersh, T.G., Fagniez, P.L., Le Bourgeois, J.P., Piedbois, P. J. Natl. Cancer Inst. (1997) [Pubmed]
  35. Late effects of low-dose adjuvant chemotherapy in colorectal cancer. Boice, J.D., Greene, M.H., Keehn, R.J., Higgins, G.A., Fraumeni, J.F. J. Natl. Cancer Inst. (1980) [Pubmed]
  36. Rapid reversible changes in the rate of histone gene transcription and histone mRNA levels in mouse myeloma cells. Graves, R.A., Marzluff, W.F. Mol. Cell. Biol. (1984) [Pubmed]
  37. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. Hohn, D., Melnick, J., Stagg, R., Altman, D., Friedman, M., Ignoffo, R., Ferrell, L., Lewis, B. J. Clin. Oncol. (1985) [Pubmed]
  38. Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2'-deoxyuridine. Hohn, D.C., Stagg, R.J., Price, D.C., Lewis, B.J. J. Clin. Oncol. (1985) [Pubmed]
WikiGenes - Universities